R 1487 

R 1487 is an orally active and highly selective p38α mitogen-activated protein kinase inhibitor. R 1487 can be used in the study of rheumatoid arthritis^[1].

388.37

C₁₉H₁₈F₂N₄O₃

449811-92-1

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. David M. Goldstein *, Michael Soth *, Tobias Gabriel , Nolan Dewdney , Andreas Kuglstatter , Humberto Arzeno , Jeffrey Chen , William Bingenheimer , Stacie A. Dalrymple , James Dunn , Robert Farrell , Sandra Frauchiger , JoAnn La Fargue , Manjiri Ghate , Bradford Graves , Ronald J. Hill , Fujun Li , Renee Litman , Brad Loe , Joel McIntosh , Daniel McWeeney , Eva Papp , Jaehyeon Park , Harlan F. Reese , Richard T. Roberts , David Rotstein , Bong San Pablo , Keshab Sarma , Martin Stahl , Man-Ling Sung , Rebecca T. Suttman , Eric B. Sjogren , Yunchou Tan , Alejandra Trejo , Mary Welch , Paul Weller , Brian R. Wong , and Hasim Zecic . Discovery of 6-(2,4-Difluorophenoxy)-2-[3-hydroxy-1-(2-hydroxyethyl)propylamino]-8-methyl-8H-pyrido[2,3-d]pyrimidin-7-one (Pamapimod) and 6-(2,4-Difluorophenoxy)-8-methyl-2-(tetrahydro-2H-pyran-4-ylamino)pyrido[2,3-d]pyrimidin-7(8H)-one (R1487) as Orally Bioavailable and Highly Selective Inhibitors of p38α Mitogen-Activated Protein Kinase. J. Med. Chem., 2011, 54 (7), pp 2255-2265 DOI: 10.1021/jm101423y Publication Date (Web): March 4, 2011

  [2]. Goldstein DM, et al. Discovery of 6-(2,4-difluorophenoxy)-2-[3-hydroxy-1-(2-hydroxyethyl)propylamino]-8-methyl-8H-pyrido[2,3-d]pyrimidin-7-one (pamapimod) and 6-(2,4-difluorophenoxy)-8-methyl-2-(tetrahydro-2H-pyran-4-ylamino)pyrido[2,3-d]pyrimidin-7(8H)-one (R1487) as orally bioavailable and highly selective inhibitors of p38α mitogen-activated protein kinase. J Med Chem. 2011 Apr 14;54(7):2255-65.  [Content Brief]